These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 25550930)

  • 1. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    Int J Clin Exp Med; 2014; 7(11):4191-8. PubMed ID: 25550930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease.
    Tada T; Saibara T; Ono M; Takahashi H; Eguchi Y; Hyogo H; Kawanaka M; Kumada T; Toyoda H; Yasuda S; Nakajima A; Yoneda M; Tanaka S; Shimada K; Hoshino H; Aishima S; Kage M; Sumida Y
    Eur J Gastroenterol Hepatol; 2021 Nov; 33(11):1451-1458. PubMed ID: 34334708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
    Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
    Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis.
    Eguchi A; Iwasa M; Yamada M; Tamai Y; Shigefuku R; Hasegawa H; Hirokawa Y; Hayashi A; Okuno K; Matsushita Y; Nakatsuka T; Enooku K; Sakaguchi K; Kobayashi Y; Yamaguchi T; Watanabe M; Takei Y; Nakagawa H
    Hepatol Commun; 2022 Aug; 6(8):1987-1999. PubMed ID: 35485207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis.
    Jiang Y; Han T; Zhang ZG; Zhang Y; Qi FX
    Rev Esp Enferm Dig; 2018 Jan; 110(1):19-24. PubMed ID: 29271227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
    Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.
    Mayo R; Crespo J; Martínez-Arranz I; Banales JM; Arias M; Mincholé I; Aller de la Fuente R; Jimenez-Agüero R; Alonso C; de Luis DA; Vitek L; Stritesky J; Caballería J; Romero-Gómez M; Martín-Duce A; Mugüerza Huguet JM; Busteros-Moraza JI; Idowu MO; Castro A; Martínez-Chantar ML; Ortiz P; Bruha R; Lu SC; Bedossa P; Noureddin M; Sanyal AJ; Mato JM
    Hepatol Commun; 2018 Jul; 2(7):807-820. PubMed ID: 30027139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis.
    Liu X; Wang Y; Ming Y; Song Y; Zhang J; Chen X; Zeng M; Mao Y
    PLoS One; 2015; 10(5):e0127352. PubMed ID: 25993652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between serum cytokeratin 18 and N-terminal procollagen III propeptide in patients with biopsy-proven nonalcoholic fatty liver disease.
    Kaya S; Boydak M; Aydin M; Aras İ
    Biotech Histochem; 2024 Aug; 99(6):313-319. PubMed ID: 39092622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study.
    Zhang H; Rios RS; Boursier J; Anty R; Chan WK; George J; Yilmaz Y; Wong VW; Fan J; Dufour JF; Papatheodoridis G; Chen L; Schattenberg JM; Shi J; Xu L; Wong GL; Lange NF; Papatheodoridi M; Mi Y; Zhou Y; Byrne CD; Targher G; Feng G; Zheng M
    Chin Med J (Engl); 2023 Feb; 136(3):341-350. PubMed ID: 36848175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The significance of 8-hydroxy-deoxyguanosine acid in the diagnosis of nonalcoholic steatohepatitis].
    Jiang Y; Han T; Zhang ZG; Lu SQ; Mi YQ; Xu L; Qi FX; Zhang Y; Song GD
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):34-38. PubMed ID: 28056321
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease.
    Manco M; Panera N; Crudele A; Braghini MR; Bianchi M; Comparcola D; De Vito R; Maggiore G; Alisi A
    Pediatr Res; 2022 Jun; 91(7):1781-1786. PubMed ID: 34331020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.